BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 2846699)

  • 21. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution.
    Sasaki A; Jain RK; Maghazachi AA; Goldfarb RH; Herberman RB
    Cancer Res; 1989 Jul; 49(14):3742-6. PubMed ID: 2500233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.
    Harel-Bellan A; Bertoglio J; Quillet A; Marchiol C; Wakasugi H; Mishall Z; Fradelizi D
    J Immunol; 1986 Apr; 136(7):2463-9. PubMed ID: 3005412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.
    Vose BM; Bonnard GD
    J Immunol; 1983 Feb; 130(2):687-93. PubMed ID: 6600251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherent lymphokine-activated natural killer cells in normal and severe combined immunodeficiency mice: large granular lymphocytes with natural killer cell phenotype and high cytolytic activity.
    Chang HL; Zaroukian MH; Morrison MH; Esselman WJ
    Nat Immun Cell Growth Regul; 1989; 8(2):89-99. PubMed ID: 2788243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in homing receptor expression on murine lymphokine-activated killer cells during IL-2 exposure.
    Steen PD; McGregor JR; Lehman CM; Samlowski WE
    J Immunol; 1989 Dec; 143(12):4324-30. PubMed ID: 2687380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
    Schwarz RE; Hiserodt JC
    J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells.
    Reynolds CW; Timonen T; Herberman RB
    J Immunol; 1981 Jul; 127(1):282-7. PubMed ID: 7240744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
    Merluzzi VJ; Trail PA; Last-Barney K
    J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.
    Uchida A; Moore M
    J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precursor phenotype of lymphokine-activated killer cells in the mouse.
    Salup RR; Mathieson BJ; Wiltrout RH
    J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.